Cost drivers in the pharmacological treatment of interstitial lung disease

[1]  M. Kreuter,et al.  Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. , 2020, The Lancet. Respiratory medicine.

[2]  Jonathan H. Chung,et al.  Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline , 2020, American journal of respiratory and critical care medicine.

[3]  T. Maher,et al.  Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA , 2020, Advances in Therapy.

[4]  R. Holle,et al.  Determinants of health-related quality of life decline in interstitial lung disease , 2020, Health and Quality of Life Outcomes.

[5]  K. Brown,et al.  Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. , 2020, The Lancet. Respiratory medicine.

[6]  C. Ryerson,et al.  Progression of fibrosing interstitial lung disease , 2020, Respiratory Research.

[7]  C. Aigner.  Neue Entwicklungen in der Lungentransplantation , 2019, Der Pathologe.

[8]  M. Kreuter,et al.  The therapy of idiopathic pulmonary fibrosis: what is next? , 2019, European Respiratory Review.

[9]  M. Kreuter,et al.  Economic burden of incident interstitial lung disease (ILD) and the impact of comorbidity on costs of care. , 2019, Respiratory medicine.

[10]  O. Hilberg,et al.  Direct and indirect economic and health consequences related to sarcoidosis in Denmark: A national register-based study. , 2019, Respiratory medicine.

[11]  M. Kolb,et al.  The natural history of progressive fibrosing interstitial lung diseases , 2019, Respiratory Research.

[12]  Gerald D. Redwine,et al.  A prospective study of patients diagnosed with sarcoidosis: factors - environmental exposure, health assessment, and genetic outlooks. , 2019 .

[13]  M. Kreuter,et al.  Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases , 2018, European Respiratory Review.

[14]  C. Neurohr,et al.  Diagnostik und Therapie bei interstitiellen Lungenerkrankungen , 2018, DMW - Deutsche Medizinische Wochenschrift.

[15]  A. Burke,et al.  Interstitial Lung Disease and Pulmonary Fibrosis: A Practical Approach for General Medicine Physicians with Focus on the Medical History , 2018, Journal of clinical medicine.

[16]  S. Birring,et al.  Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L , 2018, Respiratory Research.

[17]  K. Brown,et al.  What's in a name? That which we call IPF, by any other name would act the same , 2018, European Respiratory Journal.

[18]  A. Prasse,et al.  Sarcoidosis: a review for the internist , 2018, Internal and Emergency Medicine.

[19]  C. Neurohr,et al.  [Diagnosis and Treatment of Interstitial Lung Diseases]. , 2018, Deutsche medizinische Wochenschrift.

[20]  A. Prasse,et al.  Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry , 2017, Respiratory Research.

[21]  A. Wells,et al.  Comorbidities in interstitial lung diseases , 2017, European Respiratory Review.

[22]  C. Neurohr,et al.  [Current Developments in Lung Transplantation]. , 2017, Deutsche medizinische Wochenschrift.

[23]  Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review , 2017, Lung.

[24]  T. Welte,et al.  Lung transplantation in the spotlight: Reasons for high-cost procedures. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[25]  G. Wolff,et al.  Sarcoidosis in America. Analysis Based on Health Care Use. , 2016, Annals of the American Thoracic Society.

[26]  R. D. du Bois,et al.  Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. , 2016, Respiratory medicine.

[27]  A. Warth,et al.  Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis , 2016, PloS one.

[28]  D. Esser,et al.  Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain – results of a Delphi Panel , 2016, BMC Pulmonary Medicine.

[29]  H. Collard,et al.  Interstitial lung diseases in the hospitalized patient , 2015, BMC Medicine.

[30]  A. Wells,et al.  Smoking and interstitial lung diseases , 2015, European Respiratory Review.

[31]  A. Azuma,et al.  A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis , 2015 .

[32]  G. Rossi,et al.  Hypersensitivity Pneumonitis: A Comprehensive Review. , 2015, Journal of investigational allergology & clinical immunology.

[33]  R. Sussman,et al.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[34]  Joyce S Lee,et al.  Predicting survival across chronic interstitial lung disease: the ILD-GAP model. , 2014, Chest.

[35]  H. Collard,et al.  Update on the diagnosis and classification of ILD , 2013, Current opinion in pulmonary medicine.

[36]  M. Schwaiblmair,et al.  Drug Induced Interstitial Lung Disease , 2012, The open respiratory medicine journal.

[37]  H. Collard,et al.  Burden of illness in idiopathic pulmonary fibrosis , 2012, Journal of medical economics.

[38]  H. Collard,et al.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[39]  Abdelmonem A Afifi,et al.  Methods for improving regression analysis for skewed continuous or counted responses. , 2007, Annual review of public health.

[40]  Melinda Beeuwkes Buntin,et al.  Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. , 2004, Journal of health economics.

[41]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[42]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.